If Teva loses its case, generic Copaxone could be available as soon as this May (2014) though it would be only the daily form, not the 3-times-a-week type.
Teva is arguing that a drug like Copaxone is so complex and subtle that there is no way of knowing whether the generic form is really equivalent.
A
New York Times story (March 31) about it can be seen
here.